Cytek Biosciences Inc Cash Flow-to-Debt Ratio
Cytek Biosciences Inc cash flow-to-debt ratio. Cytek Biosciences Inc (CTKB) has a Cash Flow-to-Debt Ratio of -0.02x as of March 2026, meaning its operating cash flow of $-2.74 Million could theoretically repay 0% of its total liabilities ($121.47 Million) in one year. Check Cytek Biosciences Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cytek Biosciences Inc (2019–2025)
Cash flow-to-debt ratio of Cytek Biosciences Inc from 2019 to 2025. Historical debt coverage capacity for Cytek Biosciences Inc across 7 annual periods. Check Cytek Biosciences Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cytek Biosciences Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Cytek Biosciences Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Cytek Biosciences Inc. For the full cash flow conversion analysis, see Cytek Biosciences Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.04x | $-4.69 Million | $119.80 Million | ▼ -116.0% |
| 2024 | 0.24x | $25.38 Million | $103.76 Million | ▲ +369.6% |
| 2023 | 0.05x | $5.28 Million | $101.39 Million | ▲ +140.0% |
| 2022 | -0.13x | $-12.23 Million | $93.93 Million | ▼ -262.9% |
| 2021 | 0.08x | $4.63 Million | $57.92 Million | ▲ +24.5% |
| 2020 | 0.06x | $15.16 Million | $236.01 Million | ▲ +152.3% |
| 2019 | -0.12x | $-13.75 Million | $112.06 Million | — |